ArticleEvidence-based complementary and alternative medicine : eCAM2015
Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes.
Article in Evidence-based complementary and alternative medicine : eCAM, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 68 citations in OpenAlex.
- Medicinal Plants: A Promising Therapeutic Approach for Addressing Antimicrobial Resistance.International journal of molecular sciences · 2026Review
- Article
- Unlocking the potential of plant polyphenols: advances in extraction, antibacterial mechanisms, and future applications.Food science and biotechnology · 2025Review
- Research Progress on the Antibacterial Activity of Natural Flavonoids.Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial Potential of Polyphenols: Mechanisms of Action and Microbial Responses-A Narrative Review.Antioxidants (Basel, Switzerland) · 2025Review
- An alternative approach to combat multidrug-resistant bacteria: new insights into traditional Chinese medicine monomers combined with antibiotics.Advanced biotechnology · 2025Review
- A Narrative Review of the Biological Activities ofJournal of experimental pharmacology · 2025Review
- Antibacterial phenolic compounds from the flowering plants of Asia and the Pacific: coming to the light.Pharmaceutical biology · 2024Review
- Article
- Screening Tests for the Interaction ofAntibiotics (Basel, Switzerland) · 2024Article
- The Molecular Mechanisms and Therapeutic Potential of Cranberry, D-Mannose, and Flavonoids against Infectious Diseases: The Example of Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Therapeutic potential activity of quercetin complexes against Streptococcus pneumoniae.Scientific reports · 2024Article
- Taxifolin as a Metallo-β-Lactamase Inhibitor in Combination with Augmentin against Verona Imipenemase 2 ExpressingMicroorganisms · 2023Article
- Ceftazidime-assisted synthesis of ultrasmall chitosan nanoparticles for biofilm penetration and eradication of Pseudomonas aeruginosa.Scientific reports · 2023Article
- Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach.Nanomaterials (Basel, Switzerland) · 2023Article
- Quercetin: Synergistic Interaction with Antibiotics against Colistin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- CID12261165, a flavonoid compound as antibacterial agents against quinolone-resistant Staphylococcus aureus.Scientific reports · 2023Article
- Synergistic Interaction betweenEvidence-based complementary and alternative medicine : eCAM · 2023Article
- Bioactivity and Therapeutic Potential of Kaempferol and Quercetin: New Insights for Plant and Human Health.Plants (Basel, Switzerland) · 2022Review
- Molecular Basis for Luteolin as a Natural TatD DNase Inhibitor inInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus pyogenes causes streptococcal toxic shock syndrome. The recommended therapy has been often failure through the interfering of beta-lactamase-producing bacteria (BLPB). The present study was to investigate antibacterial activity, synergy, and modes of action of luteolin and quercetin using alone and plus ceftazidime against S. pyogenes. The MICs of ceftazidime, luteolin, and quercetin against all S. pyogenes were 0.50, 128, and 128 µg mL(-1), respectively. A synergistic effect was exhibited on luteolin and quercetin plus ceftazidime against these strains at fractional inhibitory concentration indices 0.37 and 0.27, respectively, and was confirmed by the viable count. These combinations increased cytoplasmic membrane (CM) permeability, caused irregular cell shape, peptidoglycan, and CM damage, and decreased nucleic acid but increased proteins in bacterial cells. Enzyme assay demonstrated that these flavonoids had an inhibitory activity against β-lactamase. In summary, this study provides evidence that the inhibitory mode of action of luteolin and quercetin may be mediated via three mechanisms: (1) inhibiting of peptidoglycan synthesis, (2) increasing CM permeability, and (3) decreasing nucleic acid but increasing the protein contents of bacterial cells. So, luteolin and quercetin propose the high potential to develop adjunct to ceftazidime for the treatment of coexistence of the BLPB and S. pyogenes infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.